2022
DOI: 10.51821/85.2.9775
|View full text |Cite
|
Sign up to set email alerts
|

Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients : what do we know so far ?

Abstract: Metabolic dysfunction-associated fatty liver disease (MAFLD) is the evidence of steatosis in the setting of a metabolic risk condition such as type 2 diabetes mellitus (T2DM). Indeed, T2DM and liver steatosis share common pathophysiological mechanisms, and one can lead to the other. MAFLD can progress from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis as well as hepatocellular carcinoma (HCC). Because of the lack / disparity of guidelines for MAFLD screening, which is asympto… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
19
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 23 publications
(19 citation statements)
references
References 70 publications
0
19
0
Order By: Relevance
“…However, it appears that improvement of glycemic control in patients with co-existent NAFLD and diabetes may be associated with an improvement in NAFLD independently of the lost weight [ 21 ]. Glycemic outcomes cannot be considered outside the need to tackle metabolic traits such as dyslipidemia or obesity, which improves the liver condition in patients with or without diabetes [ 22 ].…”
Section: Basic Concepts In the Management Of Patients With T2dm And N...mentioning
confidence: 99%
“…However, it appears that improvement of glycemic control in patients with co-existent NAFLD and diabetes may be associated with an improvement in NAFLD independently of the lost weight [ 21 ]. Glycemic outcomes cannot be considered outside the need to tackle metabolic traits such as dyslipidemia or obesity, which improves the liver condition in patients with or without diabetes [ 22 ].…”
Section: Basic Concepts In the Management Of Patients With T2dm And N...mentioning
confidence: 99%
“…This is mainly present at the peripheral (muscle) level and not in the liver according to the hyperinsulinemic and euglycemic clamp experiments (120). Among the causes of CLD, MAFLD is of course also associated with insulin resistance, before the development of cirrhosis (125). More simply than with the clamp, insulin resistance can also be evaluated by the homeostasis model assessment of IR (HOMA-IR) (126).…”
Section: Insulin Resistancementioning
confidence: 99%
“…Based on a cross-sectional analysis of the 2017–2020 cycle of National Health and Nutrition Examination Survey (NHANES) in the US population, the prevalence of steatotic liver disease (SLD) was 42.1%, and among them, 89.4%, 7.7%, 2.4%, 0.4%, and 0.1% were defined as MASLD, MetALD (MASLD + significant alcohol consumption), MASLD-viral hepatitis, alcoholic liver disease (ALD) (significant alcohol consumption without metabolic dysfunction), and cryptogenic, respectively ( 6 ). MAFLD shares insulin resistance and compensatory portal or systemic hyperinsulinemia with T2DM as common pathophysiological mechanisms; meanwhile, fat accumulation in liver and alterations in both energy metabolism and inflammatory signals are also involved in these two conditions ( 7 , 8 ). Osteoporosis is characterized by the deterioration of micro-architecture in bone tissue and reduced bone mass, affects more than 200 million people globally, and has become a worldwide common chronic disease due to the significant economic burden of osteoporosis-related fracture ( 9 , 10 ).…”
Section: Introductionmentioning
confidence: 99%